Erratum (DOI:10.1016/j.juro.2008.06.038);Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

Journal of Urology

Volumn 180, Issue 4, 2008, Pages 1303-1308

  Ankerst, Donna Pauler ^a   Groskopf, Jack ^c   Day, John R ^c   Blase, Amy ^c   Rittenhouse, Harry ^c   Pollock, Brad H ^a   Tangen, Cathy ^d   Parekh, Dipen ^a   Leach, Robin J ^a,b   Thompson, Ian ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Gen Probe Incorporated   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

biological markers; human; likelihood functions; prostate cancer antigen 3; prostatic neoplasms; risk assessment

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EUROPEAN AMERICAN; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR GENE; VALIDATION PROCESS;

EID: 50949128308     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.009     Document Type: Erratum

References (20)

1. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276
2. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
3. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
4. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 294 (2005) 66
5. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
6. Parekh D.J., Ankerst D.P., Higgins B.A., Hernandez J., Canby-Hagino E., Brand T., et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68 (2006) 1152
7. Thompson I.M., Pauler Ankerst D., Chi C., Goodman P.J., Tangen C.M., Lippman S.M., et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 25 (2007) 3076
8. Hernandez D.J., Han M., Humphreys E.B., Mangold L.A., Brawer M.K., Taneja S.S., et al. External validation of the prostate cancer risk calculator. J Urol, suppl. 177 (2007) 622 abstract 1874.
9. Han M., Humphreys E.B., Hernandez D.J., Partin A.W., Roehl K.A., and Catalona W.J. Comparison between the prostate cancer risk calculator and serum PSA. J Urol, suppl. 177 (2007) 622 abstract 1875
10. Reed A., Ankerst D.P., Pollock B.H., Thompson I.M., and Parekh D.J. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol 178 (2007) 1929
11. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695
12. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
13. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587
14. Schervish M.J. Theory of Statistics (1995), Springer-Verlag Inc, New York 403
15. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837
16. Chun F.K., Briganti A., Graefen M., Porter C., Montorsi F., Haese A., et al. Development and external validation of an extended repeat biopsy nomogram. J Urol 177 (2007) 510
17. Porter C.R., Gamito E.J., Crawford E.D., Bartsch G., Presti Jr. J.C., Tewari A., et al. Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting. Urology 65 (2005) 937
18. Finne P., Finne R., Bangma C., Hugosson J., Hakama M., Auvinen A., et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111 (2004) 310
19. Wang T.J., Gona P., Larson M.G., Levy D., Benjamin E.J., Tofler G.H., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631
20. Barlow W.E., White E., Ballard-Barbash R., Vacek P.M., Titus-Ernstoff L., Carney P.A., et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98 (2006) 1204